PCORI approves $42 million in funding for comparative studies on healthcare approaches

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Patient-Centered Outcomes Research Institute Board of Governors has green-lighted nearly $42 million to fund 19 new studies comparing which healthcare approaches work best.

Thirteen of the projects will support research on which care options work best in treating a range of conditions and problems that impose high burdens on patients, caregivers, and the healthcare system. These include:

  • A $6 million study to compare the effectiveness of two types of palliative care, hospital-based versus home-based, in reducing patients’ pain, anxiety and depression.

  • A $2.7 million study to determine the effect of accupressure on relieving treatment-related symptoms in children with cancer.

  • A $2.3 million project to determine whether established treatment or a newer drug is more effective against treatment-resistant cases of Kawasaki disease, which can cause heart problems in children.

Another six projects will study ways to improve methods for conducting patient-centered outcomes research. Among them are projects on assessing the quality of communications between healthcare providers and patients, preserving patient privacy when data sets including medical information are linked, and measuring patients’ preferences.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login